FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma

Jonsson Comprehensive Cancer Center

Status: Completed

Conditions: Glioblastoma

Treatments: Procedure: Positron Emission Tomography; Procedure: Computed Tomography; Radiation: Fludeoxyglucose F-18

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT02902757

NCI-2016-00583 (Registry Identifier)

15-000409 (Other Identifier)

Details and patient eligibility

About

This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.

Full description

PRIMARY OBJECTIVES:

I. To assess very early response to therapy in glioblastoma patients using 18F-FDG PET/CT.

II. Evaluate very early changes in FDG uptake within 48 hours of start of therapy and correlate them with objective response parameters such as Response Assessment in Neuro-Oncology (RANO) and survival.

OUTLINE:

Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.

Enrollment: 7 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with histologically proven high grade glioma
• Intention to start therapy

Exclusion criteria

• Severe psychiatric illness
• Inability to give written consent
• Breast feeding / pregnancy

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

7 participants in 1 patient group

Treatment (FDG PET/CT)

Experimental group

Description:

Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.

Treatment:

Radiation: Fludeoxyglucose F-18

Procedure: Computed Tomography

Procedure: Positron Emission Tomography